At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02137 BRII-B
Early Closed 12-31 12:08:27
1.410
-0.010
-0.70%
High1.440Low1.380Vol749.50K
Open1.420D1 Closing1.420Amplitude4.23%
Mkt Cap1.02BTradable Cap1.02BTotal Shares721.00M
T/O1.05MT/O Rate0.10%Tradable Shares721.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-Brii Biosciences And OpenBench Announce AI-Driven Collaboration For Proprietary Technology Platform
Reuters  ·  12-11
BRIEF-Brii Biosciences And OpenBench Announce AI-Driven Collaboration For Proprietary Technology Platform
Brii Biosciences and Openbench Announce AI-Driven Collaboration for Proprietary Technology Platform
THOMSON REUTERS  ·  12-11
Brii Biosciences and Openbench Announce AI-Driven Collaboration for Proprietary Technology Platform
Openbench - Collaboration May Expand to Include Additional Programs
THOMSON REUTERS  ·  12-11
Openbench - Collaboration May Expand to Include Additional Programs
Openbench - to Receive Payment for Delivering Novel Leads That Meet Specific Criteria Defined by Brii Bio
THOMSON REUTERS  ·  12-11
Openbench - to Receive Payment for Delivering Novel Leads That Meet Specific Criteria Defined by Brii Bio
Openbench - Brii Bio to Gain Exclusive Rights to Leads and Co's Technology
THOMSON REUTERS  ·  12-11
Openbench - Brii Bio to Gain Exclusive Rights to Leads and Co's Technology
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
Tiger Newspress  ·  12-04
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
Brii Biosciences (02137) Releases Monthly Return for November 2025
Bulletin Express  ·  12-03
Brii Biosciences (02137) Releases Monthly Return for November 2025
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Tiger Newspress  ·  12-03
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
Tiger Newspress  ·  11-26
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Tiger Newspress  ·  11-24
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Hong Kong Stocks Movement | Biotech Concept Stocks Lead Declines as BD Deals Cool and Rate Cut Expectations Fade
Stock News  ·  11-21
Hong Kong Stocks Movement | Biotech Concept Stocks Lead Declines as BD Deals Cool and Rate Cut Expectations Fade
Brii Biosciences Limited (Stock Code: 2137) Announces Revised Nomination Committee Terms
Bulletin Express  ·  11-16
Brii Biosciences Limited (Stock Code: 2137) Announces Revised Nomination Committee Terms
Brii Biosciences (2137) Presents Phase 2 ENSURE Study Results at AASLD 2025
Bulletin Express  ·  11-10
Brii Biosciences (2137) Presents Phase 2 ENSURE Study Results at AASLD 2025
BRII-B (02137) Presents Breakthrough Phase II ENSURE Study Data at 2025 AASLD Conference
Stock News  ·  11-10
BRII-B (02137) Presents Breakthrough Phase II ENSURE Study Data at 2025 AASLD Conference
Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy
Reuters  ·  11-10
Brii Biosciences Reports Positive Phase 2 ENSURE Study Results for Hepatitis B Therapy
Brii Biosciences (Stock Code: 2137) Publishes Phase 2 ENSURE Study Results in Nature Medicine
Bulletin Express  ·  11-07
Brii Biosciences (Stock Code: 2137) Publishes Phase 2 ENSURE Study Results in Nature Medicine
BRII-B (02137): ENSURE Phase II Study Results Published in Nature Medicine
Stock News  ·  11-07
BRII-B (02137): ENSURE Phase II Study Results Published in Nature Medicine
Brii Biosciences Reports Phase 2 ENSURE Study Results on HBV Cure Strategy in Nature Medicine
Reuters  ·  11-07
Brii Biosciences Reports Phase 2 ENSURE Study Results on HBV Cure Strategy in Nature Medicine
Brii Biosciences (02137) Announces 613,412-Share Increase in October 2025
Bulletin Express  ·  11-05
Brii Biosciences (02137) Announces 613,412-Share Increase in October 2025
BRII-B Grants 600,000 Share Options
Deep News  ·  11-02
BRII-B Grants 600,000 Share Options

Introduction

Company Name.
BRII-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Brii Biosciences Ltd is a biotechnology company principally focused on developing therapies for infectious diseases and central nervous system diseases. The Company's HBV portfolio products include the proprietary therapeutic vaccine BRII-179, the siRNA BRII-835 (elebsiran), and the neutralizing antibody BRII-877 (tobevibart). The Company owns a broad pipeline of multiple innovative drug candidates that focus on infectious diseases and central nervous system diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases. The Company mainly conducts its businesses in China market.
Issue price:
--